Localized Prostate Cancer: Vitality

NQF ENDORSEMENT STATUS: Not Endorsed  |  NQF ID: 9999  |  MEASURE TYPE: Outcome  |  INFO AS OF: Not available  |  CMIT ID: 5657  |  REVISION: 1
The percentage of non-metastatic prostate cancer patients with a clinically-significant change in vitality from baseline to follow-up, as measured by the validated Expanded Prostate Inventory Composite (EPIC) patient-reported outcome (EPIC-26 or EPIC-50).
Info As Of Not available
Description The percentage of non-metastatic prostate cancer patients with a clinically-significant change in vitality from baseline to follow-up, as measured by the validated Expanded Prostate Inventory Composite (EPIC) patient-reported outcome (EPIC-26 or EPIC-50).
Numerator Patients with a clinically-significant change in vitality from baseline to follow-up. Numerator definitions: Vitality is measured as the Vitality/Hormonal domain score via the EPIC-26 or EPIC-50 at baseline (0-6 months prior to the start of surgery or radiation at the reporting facility) AND follow up (1 year ( 3 months) after the date of surgery or the start of a radiation regimen at the reporting facility) Clinically significant change is defined in Skolarus et al., 2015.
Denominator All non-metastatic prostate cancer patients undergoing radiation or surgical treatment for prostate cancer at the reporting facility. Denominator definitions: Non-metastatic is defined as AJCC 7th edition M0 (non-M1) cancer stage, regardless of T and N.
Denominator Exclusions Any patients that are unable to complete a baseline and follow-up survey due to death, language barrier, or physical or mental incapacity Patients with progression to metastatic disease during the follow up period Patients who stop treatment at or leave the reporting facility during the follow up period
Rationale Stover A, Irwin DE, Chen RC, Chera BS, Mayer DK, Muss HB, Rosenstein DL, Shea TC, Wood WA, Lyons JC, Reeve BB; Integrating Patient-Reported Outcome Measures into Routine Cancer Care: Cancer Patients' and Clinicians' Perceptions of Acceptability and Value. eGEMS. 2015 Oct. 3(1): 1169. Available at: http://repository.edm-forum.org/egems/vol3/iss1/17 Skolarus TA, Dunn RL, Sanda MG, Chang P, Greenfield TK, Litwin MS, Wei JT; PROSTQA Consortium. Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form. Urology. 2015 Jan;85(1):101-5. doi: 10.1016/j.urology.2014.08.044. PubMed PMID: 25530370; PubMed Central PMCID: PMC4274392. Martin NE, Massey L, Stowell C, et al. Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. European Urology. 2015 Mar; 67(3): 460-467. Available at http://europeanurology.com/article/S0302-2838(14)00845-8/fulltext/defining-a-standard-set-of-patient-centered-outcomes-for-men-with-localized-prostate-cancer.
Evidence Patient-reported outcomes (PROs) have been identified by the National Quality Forum (NQF) as both a performance gap and area of high priority for patients, physicians, and hospitals. Vitality was identified as an outcome domain to be assessed by patients in the EPIC-26 and EPIC-50 validated patient-reported outcome instruments (with performance variations identified during instrument testing) and was also identified as an important outcome for measurement in localized prostate cancer patients by an international workgroup convened by the International Consortium for Health Outcomes Measurement (ICHOM). PCHs will be able to identify variation, less-than-optimal performance, and/or disparities in care through the collection of this measure (the Vitality/Hormonal domain of the EPIC-26, or EPIC-50 validated surveys). International Consortium for Health Outcomes Measurement (ICHOM); Localized Prostate Cancer Standard Set. May 2015. (available at www.ichom.org)
Steward The University of Texas MD Anderson Cancer Center
Contact Not available
Measure Developer Not available
Development Stage Not available
Measure Type Outcome
Meaningful Measure Area Not available
Healthcare Priority Making Care Safer by Reducing Harm Caused in the Delivery of Care
eCQM Spec Available Not Available
NQF Endorsement Status Not Endorsed
NQF ID 9999  (NQF Website )
Last NQF Update Not available
Target Population Age Not Specified
Target Population Age (High) Not available
Target Population Age (Low) Not available
Reporting Level Not available
Conditions Malignant Neoplasm (Cancer)
Subconditions Prostate Cancer
Care Settings

  Core Measure Set  :   Not available


Measure Group Group Identifier Actions
There are no relationships associated with the measure at this time.
Info As Of Not Available
Program / Model Notes
Data Sources Registry
Record review
Survey
Purposes Not available
Quality Domain Not available
Reporting Frequency Not available
Impacts Payment Not available
Reporting Status Unknown
Data Reporting Begin Date Not Available
Data Reporting End Date Not Available
Milestone Effective Date Comments Links Other Data Actions
Considered 2016-12-01 Not available
MUC Year 2016
MUC ID MUC16-381
Reference 1900-01-01 Not available
There are no links associated with the measure at this time.